Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma.
Daniel P, Meehan B, Sabri S, Jamali F, Sarkaria JN, Choi D, Garnier D, Kitange G, Glennon KI, Paccard A, Karamchandani J, Riazalhosseini Y, Rak J, Abdulkarim B.
Daniel P, et al.
Neurooncol Adv. 2022 May 23;4(1):vdac076. doi: 10.1093/noajnl/vdac076. eCollection 2022 Jan-Dec.
Neurooncol Adv. 2022.
PMID: 35795471
Free PMC article.